Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amino acid peritoneal dialysis solution for malnutrition in peritoneal dialysis patients
ChiCTR2500101290Phase 4Not yet recruiting
- Sponsor
- Xijing Hospital
- Start
- Apr 2025
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of amino acid peritoneal dialysis solution, compound alpha-ketoacid tablets and Dianeal in end-stage kidney disease (ESKD) (3 arms), sponsored by Xijing Hospital. Primary endpoint: Change from baseline in serum albumin and prealbumin at 6 months. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
amino acid peritoneal dialysis solutioncompound alpha-ketoacid tabletsDianeal
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on ChiCTR2500101290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500101290.